Ondine Biomedical (LON:OBI) Stock Price Up 2.7% – Still a Buy?

Ondine Biomedical Inc. (LON:OBI) shares shot up 2.7% on Friday . The stock traded as high as C$9.50 and last traded at C$9.50. 174,269 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 336,312 shares. The stock had previously closed at C$9.25.

Ondine Biomedical Trading Up 2.7%

The company has a market capitalization of C$4.92 billion, a P/E ratio of -1.36 and a beta of 0.10. The company has a debt-to-equity ratio of 25.95, a current ratio of 1.36 and a quick ratio of 8.26. The business’s 50-day moving average price is C$8.90 and its two-hundred day moving average price is C$11.99.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.

Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.